Australia’s health regulator, the Therapeutic Goods Administration (TGA), has launched legal action against News Corp Australia-owned News Life Media, Mamamia.com.au, AG Therapeutics, and public relations firm Straight Up PR for allegedly breaching medicinal cannabis advertising laws.
The TGA is seeking financial penalties, claiming the companies unlawfully advertised prescription-only cannabis products, violating the Therapeutic Goods Act 1989. The Act strictly prohibits the promotion of prescription medicines, including medicinal cannabis, to the public without prior authorization.
According to the TGA, articles published by News Life Media and Mamamia featured illegal testimonials and endorsements from healthcare professionals and individuals associated with patients, which are banned under Australian advertising codes. The watchdog also accused AG Therapeutics of using euphemisms like “plant medicine” in its marketing while promoting cannabis as a treatment for serious health conditions across its website and social media platforms.
TGA head Anthony Lawler said the parties involved had previously received multiple warnings regarding the unlawful promotion of therapeutic goods. Despite these alerts, the alleged advertising continued.
News Corp Australia, a unit of global media giant News Corp (NASDAQ:NWSA), has not responded to media inquiries about the proceedings. The case highlights the growing scrutiny over cannabis advertising and the regulator’s commitment to enforcing compliance in the rapidly expanding medicinal cannabis sector.
The lawsuit signals a warning to media outlets, natural health brands, and PR firms engaging in unapproved promotions of prescription therapies. As cannabis becomes more mainstream in Australia, businesses are urged to align with legal frameworks to avoid regulatory penalties and reputational damage.
This case also emphasizes the importance of responsible marketing in the health and wellness industry, particularly when dealing with prescription-only products like medicinal cannabis.


AstraZeneca Halts Phase III Volrustomig Lung Cancer Trial After Efficacy Setback
Alcohol is one of the most dangerous drugs, yet its presence is ubiquitous in social settings and celebrations
SEC Seeks ISS Client Voting Records in Proxy Adviser Probe
EQT Plans €1.7 Billion Sale of Parques Reunidos Stake
France Battles Mediterranean Wildfires as Heatwave Fuels Fire Risk
GLP-1 Weight-Loss Drug Use Surges Among U.S. Children
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss
SMBC Eyes 20% VPBank Stake in Vietnam Expansion
Maduro Seeks Dismissal of US Drug Trafficking Charges
Meta Connect Spotlights Camera-Free Smart Glasses Amid Privacy Concerns
US Backs Musk in Fight Against EU’s €120 Million X Fine
Trump Signs Order to Cut Routine Childhood Vaccines
Nvidia-Groq AI Chip Deal Faces U.S. Antitrust Probe
Moderna Short Sellers Hit With $4.8 Billion Loss as Stock Soars
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 



